Clinical trials: Neurodegenerative Diseases
Alzheimer Disease, MCI
Validation Study of a New Digital Diagnostic and Treatment Test Based on Interactive Video Games for Alzheimer's Disease
This study aims to validate a novel, non-invasive diagnostic and digital therapeutic approach for Alzheimer's Disease (AD), centered on an interactive video game called BGaze Therapy.
- Trial name
- EyeAD (NCT06963879)
- Testing
- Bgaze Therapy, Bgaze Attention Task
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Braingaze
Parkinson's Disease
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with…
- Trial name
- NCT04875962
- Testing
- UCB0599
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Amyotrophic Lateral Sclerosis
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04326283
- Testing
- Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- Genuv Inc.
Mild-moderate Alzheimer's Disease
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil
- Trial name
- NCT03055741
- Testing
- Donepezil, DHP1401
- Where
- 16 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Healthy Volunteers, Alzheimer Disease
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07787182
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson's Disease
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
An extension study for participants who have completed a prior VY-AADC01 clinical study
- Trial name
- NCT03733496
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.
- Trial name
- NCT02006290
- Testing
- PF-06412562
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Alzheimer's Disease
Exploratory and Safety Study of [F-18]W372
PHASE: Phase 0, Exploratory Study OBJECTIVES: To collect drug safety, bio-distribution and dosimetry data, to begin collection of PET/CT imaging data, to acquire experience to improve study design and the conduct of future…
- Trial name
- NCT00954369
- Testing
- [F-18]W372
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Alzheimer Disease
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
The objective of this study is to evaluate the efficacy and safety of donepezil transdermal patch in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT03197740
- Testing
- Donepezil patch, aricept Tab
- Where
- South Korea
- Volunteers
- 399 people
- Sponsor
- Icure Pharmaceutical Inc.
Parkinson's Disease
Variable Frequency Stimulation of Subthalamic Nucleus for Freezing of Gait in Parkinson's Disease
This is the first study on the effect of the variable frequency stimulation (VFS) on Freezing of gait (FOG) in Parkinson's disease (PD) patients with STN DBS.
- Trial name
- NCT02601144
- Testing
- Deep Brain Stimulation
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Alzheimer Disease
ADDIA Chronobiological Study
The present single center clinical chronobiological study on 24 subjects (12 patients with mild to moderate form of Alzheimer's disease and 12 Healthy subjects) aims at characterizing the ADDIA biomarkers: a) blood cell-based…
- Trial name
- NCT02973971
- Testing
- volumeric MRI
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Parkinson's Disease
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
The purpose of this study is to the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa…
- Trial name
- NCT02774564
- Testing
- BIA 3-202, Sinemet®
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer Disease
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.
- Trial name
- NCT03184467
- Testing
- Normal Saline 0.9%, GV1001 0.56 mg, GV1001 1.12 mg
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- GemVax & Kael
AMN, AMN Gene Mutation
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
This is a Phase 1/2 randomized, blinded, dose-escalation study to evaluate the safety and efficacy of intrathecal (IT) administration of SBT101, a recombinant adeno-associated virus serotype 9 (AAV9) containing a functional copy…
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- PROPEL (NCT05394064)
- Testing
- SBT101 Treatment
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 9 people
- Sponsor
- SwanBio Therapeutics, Inc.
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
- Trial name
- NCT02162264
- Testing
- Donepezil Hydrochloride
- Where
- Japan
- Volunteers
- 8,662 people
- Sponsor
- Eisai Co., Ltd.
Parkinson's Disease
BIIB014 Phase 2a Monotherapy
To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.
- Trial name
- NCT00451815
- Testing
- active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
- Sponsor
- Biogen
Alzheimer Disease
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565291
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.